Scientific Research of Metabolic Bloom
CLINICAL STUDIES ON THE FOLLOWING INGREDIENTS:
NICOTINAMIDE MONONUCLEOTIDE (NMN)
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Abstract
Overview: This is the primary human dose-ranging trial for NMN, and the source of the 300 mg dose used in Metabolic Bloom. It's a randomized, multicenter, double-blind, placebo-controlled trial designed specifically to test whether the NAD+-boosting and healthspan effects seen in animal studies actually translate to humans, and at what dose.
Methods: 80 healthy middle-aged and older adults (ages 40–65) across two clinical sites in India were randomized into four groups: placebo, 300 mg/day NMN, 600 mg/day NMN, or 900 mg/day NMN, taken once daily before breakfast for 60 days. The primary objective was blood NAD+ concentration. Secondary measures included the six-minute walk test, the SF-36 quality-of-life questionnaire, blood biological age (via the Aging.AI algorithm), and HOMA-IR (a measure of insulin resistance). All measures were taken at baseline, day 30, and day 60.
Results: Blood NAD+ concentration increased in a dose-dependent way, with the 600 mg and 900 mg groups showing the highest increases; the 300 mg group also increased, but by a smaller amount. Six-minute walking distance increased significantly more in all three NMN-treated groups (300 mg, 600 mg, and 900 mg) compared to placebo, at both day 30 and day 60 — with the longest walking distances in the 600 mg and 900 mg groups. Blood biological age increased significantly in the placebo group over the 60 days but stayed essentially flat in all three NMN groups, creating a significant difference between treated and placebo groups. SF-36 scores improved significantly more in all three treated groups compared to placebo, with the exception of the 300 mg group specifically at day 30 (it caught up by day 60). HOMA-IR showed no statistically significant differences between any NMN group and placebo. No safety issues were identified through adverse event monitoring, lab work, or clinical exams — NMN was well tolerated at all three doses.
Conclusion: The authors conclude that NMN supplementation is safe and well tolerated at doses up to 900 mg/day in this population, that blood NAD+ increases in a dose-dependent way, and that even the lowest dose tested (300 mg) produced measurable improvements in physical performance and self-reported health compared to placebo — though the 600 mg and 900 mg doses generally showed larger effects.
Source: Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PMID: 36482258.
https://pubmed.ncbi.nlm.nih.gov/36482258/
Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue
Abstract
Overview: This is the foundational study behind the "NAD+ declines with age" claim used throughout the copy. It's not an NMN supplementation study — it's a direct measurement of NAD+ levels in human tissue across the lifespan, which is what makes the case for why replenishing NAD+ (via NMN) might matter in the first place.
Methods: Researchers obtained skin tissue samples from 49 patients undergoing unrelated surgical procedures, ranging in age from newborn (0–1 year) to 77 years old, at Sydney Adventist Hospital. All samples came from non-sun-exposed pelvic skin, to control for UV-driven skin damage as a confounding factor. Researchers measured NAD+ levels, DNA damage (via phosphorylated H2AX), PARP activity (a NAD+-consuming DNA repair enzyme), SIRT1 activity, and lipid peroxidation (a marker of oxidative stress) in each sample.
Results: NAD+ levels showed a strong, statistically significant negative correlation with age in both males (r = −0.706, p = 0.0001) and females (r = −0.537, p = 0.01). DNA damage increased significantly with age in both sexes. PARP activity increased significantly with age in males and was inversely correlated with NAD+ levels (r = −0.638, p = 0.0003) — meaning as PARP activity went up, NAD+ went down, consistent with PARP consuming NAD+ during DNA repair. Lipid peroxidation (oxidative stress) increased significantly with age in males but not significantly in females. SIRT1 activity declined significantly with age in post-pubescent males but not in females.
Conclusion: This was the first study to directly measure and confirm that NAD+ levels decline with age in human tissue (skin specifically), and the authors propose a mechanism: oxidative DNA damage accumulates with age, which hyperactivates PARP, which in turn consumes and depletes NAD+. They note this could have downstream effects on ATP production, DNA repair capacity, and SIRT1-driven cellular signaling — all processes NAD+ is required for.
Source: Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue. PLoS ONE. 2012;7(7):e42357.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042357
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
Abstract
Overview: This trial tests NMN specifically in the context of exercise performance — pairing supplementation with actual training, rather than looking at NMN in isolation.
Methods: 48 young and middle-aged recreationally-trained runners from the Guangzhou Pearl River running team were randomized into four groups: placebo, 300 mg/day NMN, 600 mg/day NMN, or 1200 mg/day NMN, for six weeks. All participants continued their normal training schedule (40–60 minute sessions, 5–6 times per week) throughout. Cardiopulmonary exercise testing was done at baseline and after six weeks to measure oxygen uptake (VO2), VO2 as a percentage of max (VO2max%), and power output at the first and second ventilatory thresholds.
Results: VO2, VO2max%, and power at both ventilatory thresholds increased significantly more in the medium (600 mg) and high (1200 mg) dose groups compared to placebo. There was no significant difference between groups in VO2max itself, O2-pulse, VO2 relative to work rate, or peak power. The 300 mg (low) dose group's results are described as intermediate — the paper's headline framing is that "600 to 1200 mg/day" drove the clearest aerobic capacity improvements, with muscle oxygen utilization improving further at higher doses.
Conclusion: The authors conclude that NMN increases aerobic capacity during exercise training in humans, and that the mechanism is most likely improved oxygen utilization at the level of skeletal muscle — not an increase in cardiac output or lung function, since the more central measures (VO2max, peak power) didn't change.
Source: Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021;18(1):54. PMID: 34238308.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8265078/
Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study
Abstract
Overview: This study is unique in the NMN literature for testing whether the time of day NMN is taken changes its effects — specifically looking at sleep, daytime fatigue, and physical function in older adults, rather than athletic performance.
Methods: 108 adults aged 65 and older were randomized into four groups: NMN taken in the morning, NMN taken in the afternoon, placebo in the morning, or placebo in the afternoon. Dose was 250 mg/day for 12 weeks. Sleep quality was measured with the Pittsburgh Sleep Quality Index; fatigue was measured with a Japanese fatigue self-assessment questionnaire ("Jikaku-sho shirabe"); physical performance was assessed via grip strength, 5-times sit-to-stand (5-STS, a proxy for lower-limb strength), timed up-and-go, and habitual walking speed over 5 meters.
Results: A significant interaction was found between 5-STS performance and drowsiness scores. Across all groups, 5-STS improved post-intervention, and drowsiness in both PM groups (NMN and placebo) improved at mid- and post-intervention. The NMN-afternoon group showed the largest effect sizes of any group for both 5-STS (Cohen's d = 0.72) and reduced drowsiness (d = 0.64) — meaningfully larger effects than the NMN-morning group or either placebo group.
Conclusion: The authors conclude that afternoon NMN intake specifically — more so than morning intake — improved lower-limb physical function and reduced daytime drowsiness in older adults, and suggest NMN may help counteract age-related physical decline and fatigue, though they note dietary NMN intake wasn't controlled for during the trial as a limitation.
Source: Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022;14(4):755. PMID: 35215405.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8877443/
Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men
Abstract
Overview: This trial focuses specifically on strength and mobility outcomes tied to sarcopenia (age-related muscle loss) — grip strength and gait speed are both diagnostic criteria used to assess sarcopenia risk in older adults.
Methods: 65 healthy men aged 65 or older were screened for a placebo-controlled, randomized, double-blind, parallel-group trial. Participants received 250 mg/day of NMN or placebo for 6 or 12 weeks. Outcomes included blood NAD+ and NAD+-related metabolite levels, gait speed, grip strength, and skeletal muscle mass/composition.
Results: NMN supplementation was well tolerated with no significant adverse effects. Blood NAD+ and related metabolites increased significantly in the NMN group. Gait speed and grip strength both improved significantly more in the NMN group than placebo — left grip strength specifically increased by 1.3 ± 2.7 kg in the NMN group versus a decrease of 0.7 ± 2.5 kg in the placebo group (p = 0.019). Skeletal muscle mass did not differ between groups — meaning NMN improved how the muscle performed without necessarily adding muscle tissue.
Conclusion: The authors conclude that chronic oral NMN supplementation is well tolerated, reliably raises blood NAD+ in older men, and partially improves muscle performance (gait speed and grip strength specifically), suggesting it could be a therapeutic strategy worth exploring for age-related conditions like sarcopenia — while noting the effect on strength was real but partial, not a full reversal of age-related decline.
Source: Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022;8:5.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9158788/
BOVINE COLLAGEN PEPTIDES
Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study
Abstract
Overview: A clinical trial testing a low-molecular-weight collagen peptide (rich in the tripeptides Gly-Pro-Hyp) on three separate, objectively measured skin parameters — hydration, wrinkling, and elasticity — over 12 weeks.
Methods: 64 participants were randomized to receive either 1,000 mg of low-molecular-weight collagen peptide (LMWCP) or a placebo, once daily for 12 weeks. Skin hydration, wrinkling, and elasticity were measured using standardized instruments at baseline, 6 weeks, and 12 weeks.
Results: Skin hydration was significantly higher in the LMWCP group compared to placebo at both the 6-week and 12-week marks. For wrinkling, the visual assessment score and three separate wrinkle parameters were all significantly improved in the LMWCP group by week 12 compared to placebo. For elasticity, results were more mixed: one of three elasticity parameters improved significantly from the LMWCP group's own baseline by week 12, and two of three parameters were significantly higher than the placebo group by week 12. No adverse effects related to the test material were reported by any participant.
Conclusion: The authors conclude that this low-molecular-weight collagen peptide can be used as a functional food ingredient to improve skin hydration, elasticity, and wrinkling — with hydration and wrinkling showing the most consistent, clearest improvements, and elasticity showing a partial but still measurable effect.
Source: Kim DU, Chung HC, Choi J, Sakai Y, Lee BY. Oral Intake of Low-Molecular-Weight Collagen Peptide Improves Hydration, Elasticity, and Wrinkling in Human Skin: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2018;10(7):826. PMID: 29949889.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6073484/
The Effects of Dietary Supplementation with Collagen and Vitamin C and Their Combination with Hyaluronic Acid on Skin Density, Texture and Other Parameters: A Randomised, Double-Blind, Placebo-Controlled Trial
Abstract
Overview: This is the key study behind Metabolic Bloom's collagen + Vitamin C pairing — it tests collagen combined with Vitamin C at essentially the same doses used in this formula (5 g collagen / 80 mg Vitamin C), and separately tests whether adding hyaluronic acid on top makes a meaningful difference. This study is directly relevant to both the collagen and the Vitamin C ingredients in the formula, since it tests them together.
Methods: 87 women aged 40–65 completed this three-way, randomized, double-blind, placebo-controlled trial, run from February to July 2023 in Slovenia. Participants were split into three groups: a placebo group (n=29, syrup with no active ingredients), a "CP" group (n=30, 5 g hydrolyzed collagen + 80 mg Vitamin C daily), and a "CPHA" group (n=28, the same CP formula plus 30 mg hyaluronic acid). All groups took their assigned product daily for 16 weeks. Skin density, texture, wrinkle severity, elasticity, and hydration were measured using validated instrumental methods.
Results: Both active product groups (CP and CPHA) showed statistically significant improvements in dermis density, skin texture, and wrinkle severity compared to placebo. Neither active product produced a significant change in skin elasticity or hydration compared to placebo. Critically, the CPHA group (with added hyaluronic acid) did not outperform the plain CP group — the added hyaluronic acid did not provide a measurable additional benefit over collagen + Vitamin C alone.
Conclusion: The authors conclude that daily supplementation with collagen and Vitamin C meaningfully improves dermis density, skin texture, and wrinkle appearance in women aged 40–65 over 16 weeks, and that adding hyaluronic acid on top of this combination does not provide additional measurable benefit — collagen + Vitamin C alone appears to be doing the heavy lifting.
Source: Žmitek K, Žmitek J, Hristov H, Rogl Butina M, Keršmanc P, Pogačnik T. The Effects of Dietary Supplementation with Collagen and Vitamin C and Their Combination with Hyaluronic Acid on Skin Density, Texture and Other Parameters: A Randomised, Double-Blind, Placebo-Controlled Trial. Nutrients. 2024;16(12):1908.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11206740/
VITAMIN C
The Roles of Vitamin C in Skin Health
Abstract
Overview: This is a review (not a clinical trial) that explains the biochemical case for why Vitamin C matters for skin and collagen specifically — the mechanistic backbone behind the collagen + Vitamin C pairing in Metabolic Bloom. See the Žmitek et al. entry above (under Bovine Collagen Peptides) for the clinical trial that tested this pairing directly at matching doses.
Overview of findings: Human skin naturally contains high concentrations of Vitamin C, actively transported in from the bloodstream via specific transporter proteins (SVCT1 and SVCT2) since skin cells can't produce it on their own — humans, unlike most animals, can't synthesize Vitamin C at all and depend entirely on dietary intake. The review details Vitamin C's specific, non-negotiable role as a cofactor for prolyl and lysyl hydroxylase, the two enzymes responsible for stabilizing collagen's triple-helix structure; without adequate Vitamin C, these enzymes can't function properly, and newly-synthesized collagen ends up structurally unstable. Separately, the review covers Vitamin C's role as an antioxidant in skin, where it helps neutralize reactive oxygen species generated by UV exposure and regenerates vitamin E (another skin antioxidant) after it's been "used up" neutralizing free radicals. The review notes that while Vitamin C's role in collagen synthesis is extremely well established at the biochemical level (going back to why scurvy causes connective tissue breakdown), the evidence specifically for oral Vitamin C supplementation improving skin appearance in people who already have adequate Vitamin C levels is less robust than the mechanistic case would suggest, and depends heavily on baseline nutritional status.
Conclusion: The authors conclude that Vitamin C plays a clear, mechanistically well-established dual role in skin health — as a required cofactor for collagen synthesis and as an antioxidant defending against UV-driven photodamage — while noting that optimizing dietary Vitamin C intake, rather than assuming topical application alone is sufficient, may be the more reliable route to supporting these functions.
Source: Pullar JM, Carr AC, Vissers MCM. The Roles of Vitamin C in Skin Health. Nutrients. 2017;9(8):866. PMID: 28805671.
https://pubmed.ncbi.nlm.nih.gov/28805671/
GREEN TEA LEAF EXTRACT
Effect of Acute and Chronic Dietary Supplementation with Green Tea Catechins on Resting Metabolic Rate, Energy Expenditure and Respiratory Quotient: A Systematic Review
Abstract
Overview: A systematic review pooling 15 human studies to answer a specific question: do green tea catechins (the active compounds in green tea extract) measurably change how the body burns energy — specifically resting metabolic rate (RMR), total energy expenditure (EE), and respiratory quotient (RQ, a marker of whether the body is burning more fat or more carbs at rest).
Methods: Researchers searched Scopus and Google Scholar for human intervention studies (search conducted September 2020) that reported baseline and follow-up values for RMR, EE, or RQ alongside green tea catechin dosing. Eligible studies used green tea extracts with no more than 50 mg of caffeine, to isolate the effect of the catechins from caffeine's own metabolic effects. The final pool included 15 studies (499 total participants): some chronic (8–12 weeks of daily supplementation) and some acute (single-dose testing over 1–3 days). EGCG doses across the studies ranged from 100–800 mg/day.
Results: For RQ specifically (the clearest finding of the review), catechin supplementation was associated with a lower RQ — meaning a shift toward burning more fat relative to carbohydrates — across 272 subjects, and this effect appeared strongest at lower EGCG doses in the 100–300 mg range. For RMR and EE, results were mixed: some individual studies found real increases (one found a 43.82 kcal/day increase in RMR after 8 weeks; another found a 260.8 kcal/day increase, but only when green tea was combined with resistance training — green tea alone without exercise didn't produce the same RMR increase), while several other studies found no significant change in RMR or EE at all. The review's dose-response analysis found a positive correlation between catechin dose and RMR specifically, but no clear dose-response relationship for RQ.
Conclusion: The authors conclude that green tea catechins have a real, fairly consistent effect on RQ (shifting metabolism toward fat oxidation), but that the evidence for a direct RMR or total energy expenditure increase is inconsistent across studies and not yet definitive — some trials show a clear benefit (particularly when catechins are paired with exercise), while others show none. They note that low doses (100–300 mg EGCG) were where the clearest RQ effects showed up, and call for more research to define the ideal dose.
Source: Rondanelli M, Riva A, Petrangolini G, Allegrini P, Perna S, Faliva MA, Peroni G, Naso M, Nichetti M, Perdoni F, Gasparri C. Effect of Acute and Chronic Dietary Supplementation with Green Tea Catechins on Resting Metabolic Rate, Energy Expenditure and Respiratory Quotient: A Systematic Review. Nutrients. 2021;13(2):644. PMID: 33671139.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7922336/
AKKERMANSIA MUCINIPHILA
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Abstract
Overview: The first human trial ever conducted on Akkermansia muciniphila supplementation. A randomized, double-blind, placebo-controlled pilot study testing daily oral A. muciniphila (in live or pasteurized form) in overweight/obese, insulin-resistant adults.
Methods: 40 volunteers were enrolled and 32 completed the trial. Participants received a daily dose of 10^10 (10 billion) A. muciniphila bacteria, either live or pasteurized, or a placebo, for three months. Primary endpoints were safety, tolerability, and metabolic parameters (insulin resistance, circulating lipids, visceral adiposity, body mass). Secondary outcomes included gut barrier function (via plasma lipopolysaccharide levels) and gut microbiota composition.
Results: Both live and pasteurized A. muciniphila were safe and well tolerated over the three months. Compared to placebo, pasteurized A. muciniphila significantly improved insulin sensitivity (+28.62 ± 7.02%, p = 0.002), reduced insulinemia — circulating insulin levels — by 34.08 ± 7.12% (p = 0.006), and reduced plasma total cholesterol by 8.68 ± 2.38% (p = 0.02). Pasteurized A. muciniphila also produced a slight decrease in body weight (−2.27 ± 0.92 kg, p = 0.091), fat mass (−1.37 ± 0.82 kg, p = 0.092), and hip circumference (−2.63 ± 1.14 cm, p = 0.091) compared to baseline — though these three body-composition changes fell just short of standard statistical significance (p < 0.05). After three months, markers of liver dysfunction and inflammation were also reduced, while the overall structure of participants' gut microbiome was largely unaffected — meaning A. muciniphila didn't dramatically reshape the broader microbiome, it acted more specifically.
Conclusion: The authors conclude this proof-of-concept trial demonstrates A. muciniphila supplementation is safe and well tolerated in humans, and that the pasteurized form in particular produced meaningful improvements in insulin sensitivity, circulating insulin, and cholesterol — with body weight and fat mass trending in the right direction without reaching full statistical significance in this relatively small pilot study.
Source: Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019;25(7):1096-1103. PMID: 31263284.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6699990/
COLOSTRUM
Bovine Colostrum in Increased Intestinal Permeability in Healthy Athletes and Patients: A Meta-Analysis of Randomized Clinical Trials
Abstract
Overview: A meta-analysis specifically focused on whether bovine colostrum supplementation improves intestinal permeability — commonly referred to as "leaky gut" — pooling results across multiple randomized trials rather than relying on any single study.
Methods: Researchers searched PubMed, ISI Web of Science, and Scopus for relevant randomized clinical trials published up to March 2022. Ten articles met inclusion criteria and were pooled into the final meta-analysis using a random-effects model. The primary outcome measures were standard, validated gut permeability tests: the urinary lactulose/rhamnose ratio and the lactulose/mannitol ratio (both measure how much of two differently-sized sugar molecules leak through the gut wall into urine — a lower ratio indicates a tighter, less permeable gut lining), plus plasma intestinal fatty acid-binding protein (I-FABP), a blood marker of intestinal cell damage.
Results: The pooled analysis found a statistically significant reduction in the 5-hour urinary lactulose/rhamnose ratio after bovine colostrum supplementation (mean difference: −0.24, 95% CI −0.43 to −0.04), and a significant reduction in the lactulose/mannitol ratio as well (mean difference: −0.01, 95% CI −0.02 to −0.001). There was no significant difference between colostrum and control groups in plasma I-FABP levels (mean difference: 2.30, 95% CI −293.9 to 298.5) — meaning the permeability tests showed improvement, but this particular blood marker of cell damage didn't move.
Conclusion: The authors conclude that bovine colostrum supplementation is associated with a real, statistically significant improvement in gut permeability as measured by standard sugar-absorption tests, across both healthy athletes and patient populations, even though one specific blood biomarker (I-FABP) didn't show a corresponding change.
Source: Hajihashemi P, Haghighatdoost F, Kassaian N, Hoveida L, Tamizifar B, Nili H, Rahim Khorasani M, Adibi P. Bovine Colostrum in Increased Intestinal Permeability in Healthy Athletes and Patients: A Meta-Analysis of Randomized Clinical Trials. Digestive Diseases and Sciences. 2024;69(4):1345-1360. PMID: 38361147.
https://pubmed.ncbi.nlm.nih.gov/38361147/
References:
- https://pubmed.ncbi.nlm.nih.gov/36482258/
- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042357
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8265078/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8877443/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9158788/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6073484/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11206740/
- https://pubmed.ncbi.nlm.nih.gov/28805671/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7922336/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6699990/
- https://pubmed.ncbi.nlm.nih.gov/38361147/